Patents by Inventor Stefan Rose-John
Stefan Rose-John has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9765129Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.Type: GrantFiled: August 16, 2013Date of Patent: September 19, 2017Assignees: Baker Medical Research Institute, Christian-Albrechts-Universität zu KielInventors: Mark Anthony Febbraio, Stefan Rose-John
-
Patent number: 9187542Abstract: Nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule having a nucleotide sequence shown in SEQ ID: NO 1, (b) a nucleic acid molecule which encodes a peptide having an amino acid sequence shown in SEQ ID: NO 2, (c) a nucleic acid molecule whose complementary strand hybridizes to a nucleic acid molecule according to (a) or (b) and which codes for a peptide which binds to ciliary neurotrophic factor receptor (CNTFR), the peptide binding with lower affinity than ciliary neurotrophic factor to the interleukin-6 receptor (IL-6R), (d) a nucleic acid molecule whose nucleotide sequence differs from the nucleotide sequence of a nucleic acid molecule according to (c) due to the degenerated genetic code, the codon at positions 82-84 of the nucleic acid molecule according to (a) coding for a non-positively charged amino acid, and the peptide at position 28 shown in SEQ ID: NO 2 having a non-positively charged amino acid residue.Type: GrantFiled: June 13, 2012Date of Patent: November 17, 2015Assignee: CHRISTIAN-ALBRECHTS-UNIVERSITAT ZU KIELInventors: Joachim Grötzinger, Stefan Rose-John, Jürgen Scheller, Matthias Aurich
-
Publication number: 20140171620Abstract: Nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule having a nucleotide sequence shown in SEQ ID: NO 1, (b) a nucleic acid molecule which encodes a peptide having an amino acid sequence shown in SEQ ID: NO 2, (c) a nucleic acid molecule whose complementary strand hybridizes to a nucleic acid molecule according to (a) or (b) and which codes for a peptide which binds to ciliary neurotrophic factor receptor (CNTFR), the peptide binding with lower affinity than ciliary neurotrophic factor to the interleukin-6 receptor (IL-6R), (d) a nucleic acid molecule whose nucleotide sequence differs from the nucleotide sequence of a nucleic acid molecule according to (c) due to the degenerated genetic code, the codon at positions 82-84 of the nucleic acid molecule according to (a) coding for a non-positively charged amino acid, and the peptide at position 28 shown in SEQ ID: NO 2 having a non-positively charged amino acid residue.Type: ApplicationFiled: June 13, 2012Publication date: June 19, 2014Applicant: CHRISTIAN-ALBRECHTS-UNIVERSITAT ZU KIELInventors: Joachim Grötzinger, Stefan Rose-John, Jurgen Scheller, Matthias Aurich
-
Publication number: 20140140949Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.Type: ApplicationFiled: August 16, 2013Publication date: May 22, 2014Applicants: Christian-Albrechts-Universität Zu Kiel, Baker Medical Research InstituteInventors: Mark Anthony Febbraio, Stefan Rose-John
-
Publication number: 20140072984Abstract: Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 GIn113 or ASn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.Type: ApplicationFiled: June 20, 2013Publication date: March 13, 2014Applicant: Conaris Research Institute AGInventors: Joachim Grötzinger, Jürgen Scheller, Stephanie Tenhumberg, Stefan Rose-John, Georg H. Wätzig
-
Patent number: 8501696Abstract: Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 Gln113 or Asn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.Type: GrantFiled: October 15, 2008Date of Patent: August 6, 2013Assignee: Conaris Research Institute AGInventors: Joachim Grötzinger, Jürgen Scheller, Stephanie Tenhumberg, Stefan Rose-John, Georg H. Wätzig
-
Patent number: 8372389Abstract: The present invention relates to methods for preventing or treating toxicities associated with exposure to ionizing radiation or to chemotherapy. Particularly, the present invention relates to methods for preventing or treating toxicities associated with radiation or chemotherapy comprising administering to a subject in need of such treatment polypeptide complexes comprising an IL-6 linked to a soluble IL-6 receptor, the polypeptide complexes capable of preventing or treating toxicities, particularly xerostomia.Type: GrantFiled: November 27, 2008Date of Patent: February 12, 2013Assignees: Hadasit Medical Research Services and Development Ltd., Christian-Albrechts-Universitat Zu KielInventors: Jonathan H. Axelrod, Eithan Galun, Stefan Rose-John, Ytzhack Marmary
-
Patent number: 8206948Abstract: Described are codon optimized sgp130 encoding nucleic acid molecules as well as a method for the highly efficient recombinant production of sgp130 in mammalian cells or bacteria using a nucleic acid molecule of the invention.Type: GrantFiled: August 26, 2005Date of Patent: June 26, 2012Assignee: Conaris Research Institute AGInventors: Dirk Seegert, Georg Wätzig, Nikolaus Rahaus, Jessica Daecke, Stefan Rose-John
-
Publication number: 20110184220Abstract: The present invention relates to methods for preventing or treating toxicities associated with exposure to ionizing radiation or to chemotherapy. Particularly, the present invention relates to methods for preventing or treating toxicities associated with radiation or chemotherapy comprising administering to a subject in need of such treatment polypeptide complexes comprising an IL-6 linked to a soluble IL-6 receptor, the polypeptide complexes capable of preventing or treating toxicities, particularly xerostomia.Type: ApplicationFiled: November 27, 2008Publication date: July 28, 2011Inventors: Jonathan H. Axelrod, Eithan Galun, Stefan Rose-John, Ytzhack Marmary
-
Patent number: 7897145Abstract: The present invention relates to methods for treating renal failure. Particularly, the present invention relates to methods for treating renal failure by administering to a subject complexes that include a member of the IL-6 family linked to a soluble receptor of the member of the IL-6 family, or isolated polynucleotides encoding same, the complexes capable of activating a gp130 mediated signaling pathway, thereby treating acute or chronic renal failure.Type: GrantFiled: June 15, 2006Date of Patent: March 1, 2011Assignee: Hadasit Medical Research Services and Development Ltd.Inventors: Jonathan Axelrod, Daniel Barkan, Eithan Galun, Yael Nehemia, Stefan Rose-John
-
Publication number: 20100298236Abstract: Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues Thr102 Gln113 or Asn114 of the N-terminal Ig-like domain of gp130 is mutated to Tyr102, Phe113 or Leu114, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.Type: ApplicationFiled: October 15, 2008Publication date: November 25, 2010Inventors: Joachim Grötzinger, Jürgen Scheller, Stephanie Tenhumberg, Stefan Rose-John, George H. Wätzig
-
Publication number: 20100209385Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.Type: ApplicationFiled: March 28, 2008Publication date: August 19, 2010Inventors: Mark Anthony Febbraio, Stefan Rose-John
-
Publication number: 20100135952Abstract: The present invention relates to methods for treating renal failure. Particularly, the present invention relates to methods for treating renal failure by administering to a subject complexes that include a member of the IL-6 family linked to a soluble receptor of the member of the IL-6 family, or isolated polynucleotides encoding same, the complexes capable of activating a gp130 mediated signaling pathway, thereby treating acute or chronic renal failure.Type: ApplicationFiled: June 15, 2006Publication date: June 3, 2010Inventors: Jonathan Axelrod, Daniel Barkan, Eithan Galun, Yael Nehemia, Stefan Rose-John
-
Patent number: 7629147Abstract: A polypeptide-dimer comprising two soluble gp130 molecules is described, wherein at least one of said soluble gp130 molecules is covalently linked to polyethylene glycol. Furthermore, a pharmaceutical composition containing said dimer and various medical uses are described.Type: GrantFiled: February 5, 2008Date of Patent: December 8, 2009Assignee: Conaris Research Institute AGInventors: Dirk Seegert, Stefan Schreiber, Stefan Rose-John, Georg H. Watzig, Nikolaus Rahaus
-
Patent number: 7534862Abstract: A polypeptide-dimer comprising two soluble gp130 molecules is described, wherein at least one of said soluble gp130 molecules is covalently linked to polyethylene glycol. Furthermore, a pharmaceutical composition containing said dimer and various medical uses are described.Type: GrantFiled: June 23, 2004Date of Patent: May 19, 2009Assignee: Conaris Research Institute AGInventors: Dirk Seegert, Stefan Schreiber, Stefan Rose-John, Georg H. Watzig, Nikolaus Rahaus
-
Publication number: 20090010872Abstract: The present invention concerns a new designer cytokine termed H11, which is constructed by fusion of two soluble components, soluble interleukin 11 receptor (sIL-11 R) and interleukin 11 (IL-11) using their natural sequence and its use for the production of a medicament for treating or preventing a disease selected from the group consisting of a proliferative disease, a cytopathy, radiation damage, an IL-11 dependent inflammatory disorder, IL-11 dependent degenerative disorder and IL-11 dependent or mediated soft tissue disorder.Type: ApplicationFiled: May 20, 2005Publication date: January 8, 2009Inventors: Andrzej Mackiewicz, Hanna Dams-Kozlowska, Stefan Rose-John
-
Publication number: 20080227155Abstract: A polypeptide-dimer comprising two soluble gp130 molecules is described, wherein at least one of said soluble gp130 molecules is covalently linked to polyethylene glycol. Furthermore, a pharmaceutical composition containing said dimer and various medical uses are described.Type: ApplicationFiled: February 5, 2008Publication date: September 18, 2008Inventors: Dirk Seegert, Stefan Schreiber, Stefan Rose-John, Georg H. Watzig, Nikolaus Rahaus
-
Publication number: 20080199906Abstract: Described are codon optimized sgp130 encoding nucleic acid molecules as well as a method for the highly efficient recombinant production of sgp130 in mammalian cells or bacteria using a nucleic acid molecule of the invention.Type: ApplicationFiled: August 26, 2005Publication date: August 21, 2008Applicant: CONARIS RESEARCH INSTITUTE AGInventors: Dirk Seegert, Georg Watzig, Nikolaus Rahaus, Jessica Daecke, Stefan Rose-John
-
Publication number: 20070270334Abstract: A polypeptide-dimer comprising two soluble gp130 molecules is described, wherein at least one of said soluble gp130 molecules is covalently linked to polyethylene glycol. Furthermore, a pharmaceutical composition containing said dimer and various medical uses are described.Type: ApplicationFiled: June 23, 2004Publication date: November 22, 2007Inventors: Dirk Seegert, Stefan Schreiber, Stefan Rose-John, Georg Watzig, Nikolaus Rahaus
-
Patent number: 7112436Abstract: The present invention concerns a conjugate comprising two polypeptides with a mutual affinity, the polypeptides being connected with each other via a linker. This invention also concerns the use of such a conjugate to influence interactions between proteins.Type: GrantFiled: March 7, 1997Date of Patent: September 26, 2006Assignee: Angewandte Gentechnologie Systeme GmbHInventor: Stefan Rose-John